Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer (2000)
    Springer
    Annals of oncology 11 (2000), S. 101-103 
    Details
    ISSN: 1569-8041
    Keywords: antifolate ; chemotherapy ; pancreatic cancer ; thymidylate synthase inhibitor
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose:To determine the safety and activity of LY231514(ALIMTA™, MTA, pemetrexed disodium, Eli Lilly and Co.,Indianapolis, IN) in chemotherapy-naïve patients with advanced pancreaticcancer. Patients and methods:Patients with unresectable or metastaticpancreatic cancer received LY231514 600 mg/m2 as a 10–minuteinfusion every three weeks. Results:Forty-two patients were enrolled in this phase II trial.The median age was 60.3 (range 37–77) years; 79% had metastaticdisease. Neutropenia was common (40% of patients ≥ grade 3) butinfectious complications were rare. Significant anemia or thrombocytopeniaoccurred in 〈20% of patients. Non-hematologic toxicities includedgrade 2 or 3 skin reaction which was ameliorated by dexamethasone. Elevationsof bilirubin or transaminases were infrequent (〈25% of patients) anddid not require dose reductions or treatment delays. Thirty-five patientsreceived two cycles of therapy and were evaluable for response. One complete(duration 16.2 months) and one partial (duration 6.9 months) were observedresulting in an objective response rate of 5.7% for evaluable patients.In addition, 17 patients (40%) had stable disease that lasted ≥6months in 5 patients. The median survival was 6.5 months, with 28% ofpatients alive at one year. Conclusions:LY231514 is a well-tolerated agent with minimalobjective antitumor activity in pancreatic cancer. The median and one yearsurvival times, which may be important indicators in phase II trials of newagents, are of interest. Combination trials of LY231514 in pancreatic cancerare planned.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008305205159
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer (2000)
    Springer
    Investigational new drugs 18 (2000), S. 187-191 
    Details
    ISSN: 1573-0646
    Keywords: Malignant melanoma ; prostate cancer ; chemotherapy ; clinical trial
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract Introduction: CI-980 is a novel chemotherapeutic agent thatinhibits polymerization of tubulin. Preclinical studies haveindicated a high level activity of this agent against various tumorcell lines. Methods: 13 malignant melanoma patients who hadfailed prior chemotherapy and/or immunotherapy and 13 hormonerefractory prostate cancer patients, including 4 who had receivedprior chemotherapy, were treated in 2 separate NCI-supportedclinical trials. Subjects received a recommended phase II dose ofCI-980 of 4.5 mg/m2/day by continuous infusion for 72 hoursevery 3 weeks. Results: No activity was seen in either study.Toxicity was tolerable with neutropenia being the most common,significant toxicity. Among the melanoma patients, 15% and 31%developed grade 3 and grade 4 neutropenia, while 7% and 38% ofthe prostate patients developed grade 3 and grade 4 neutropenia,respectively. Conclusions: CI-980 at this dose and scheduleis ineffective against malignant melanoma and hormone refractoryprostate cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1006382014403
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...